Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...